Literature DB >> 9375673

Adrenomedullary secretion of DOPA, catecholamines, catechol metabolites, and neuropeptides.

S L Chritton1, S L Chinnow, C Grabau, M K Dousa, D Lucas, D Roddy, T L Yaksh, G M Tyce.   

Abstract

Catecholamines and their metabolites have been proposed as markers of sympathetic nervous system stimulation. However, the adrenal medulla is a rich source of catecholamines and catecholamine metabolites and may play a significant role in plasma levels of these compounds. In addition to adrenal catecholamine metabolite efflux, the role of the catecholamine precursor 3,4-dihydroxyphenylalanine (DOPA) has not been fully evaluated. The simultaneous effluxes of catecholamines, metabolites, DOPA, and neuropeptides were measured in perfusates from isolated dog adrenals. The relative abundance of compounds detected consistently during unstimulated conditions was epinephrine >> norepinephrine > 3,4-dihydroxyphenylglycol > metanephrine > normetanephrine > dopamine > 3,4-dihydroxyphenylacetic acid > 3-methoxy-4-hydroxyphenylglycol > or = DOPA >> [Met]enkephalin >> neuropeptide Y. Effluxes of analytes were not affected by cocaine and the ratios of catecholamines to metabolites increased dramatically with carbachol stimulation, consistent with negligible reuptake into adrenal cells. Thus, most of the 3,4-dihydroxyphenylglycol is expected to be derived from epinephrine and norepinephrine subsequent to translocation from chromaffin vesicles into the cytosol. The efflux of DOPA increased dramatically during stimulation with 30 microM carbachol in a calcium-dependent manner. Efflux of DOPA during the initial stabilization period of the perfusion preparation declined exponentially, in parallel with the effluxes of the catecholamines and neuropeptides but not with metabolites. Evoked release of DOPA was Ca2+-dependent. These data suggest that DOPA can be stored and released exocytotically from chromaffin granules.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9375673     DOI: 10.1046/j.1471-4159.1997.69062413.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  4 in total

1.  Changes in plasma catecholamines levels as preclinical biomarkers in experimental models of Parkinson's disease.

Authors:  A R Kim; M V Ugryumov
Journal:  Dokl Biochem Biophys       Date:  2015-10-31       Impact factor: 0.788

2.  L-DOPA sensitizes vasomotor tone by modulating the vascular alpha1-adrenergic receptor.

Authors:  Daiki Masukawa; Motokazu Koga; Anna Sezaki; Yuka Nakao; Yuji Kamikubo; Tatsuo Hashimoto; Yuki Okuyama-Oki; Aderemi Caleb Aladeokin; Fumio Nakamura; Utako Yokoyama; Hiromichi Wakui; Hiroshi Ichinose; Takashi Sakurai; Satoshi Umemura; Koichi Tamura; Yoshihiro Ishikawa; Yoshio Goshima
Journal:  JCI Insight       Date:  2017-09-21

Review 3.  Catecholamines-crafty weapons in the inflammatory arsenal of immune/inflammatory cells or opening pandora's box?

Authors:  Michael A Flierl; Daniel Rittirsch; Markus Huber-Lang; J Vidya Sarma; Peter A Ward
Journal:  Mol Med       Date:  2008 Mar-Apr       Impact factor: 6.354

Review 4.  l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson's Disease.

Authors:  Yoshio Goshima; Daiki Masukawa; Yuka Kasahara; Tatsuo Hashimoto; Aderemi Caleb Aladeokin
Journal:  Front Pharmacol       Date:  2019-10-03       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.